Drug firm Mankind Pharma Ltd on Friday (December 15) said the company has made an additional investment of £1 million in Actimed Therapeutics Ltd.
The strategic move, disclosed on December 15, signifies Mankind Pharma’s dedication to advancing treatments for cancer cachexia, amyotrophic lateral sclerosis (ALS), and various muscle wasting disorders.
This latest investment secures approximately 1.29% of the paid-up ordinary share capital of Actimed, elevating Mankind Pharma’s aggregate shareholding in the clinical-stage biopharmaceutical company to around 10.19%.
Actimed, incorporated in the United Kingdom on December 9, 2016, has been at the forefront of pioneering therapies for complex medical conditions. In the last three years, Actimed’s turnover reflects the company’s growth trajectory, with £797,919 in 2022 and £1,423,408 in 2021.
Back in January this year, Mankind Pharma had…
